But, given that the CD133 intracellular domain does not seem to be an HDAC6 target, and even so, its deacetylase activity is required to maintain CD133 stability, these data suggest the existence of an intermediary protein, an HDAC6 target involved in CD133 regulation on the cell surface in CRC. Here, HDAC6 is linked to colorectal carcinoma.